2-oxo-1,2,4,5-tetrahydro-1,3-benzodiaz epin-3-yl-piperidines used as CGRP antagonists

Details for Australian Patent Application No. 2006226544 (hide)

Owner Boehringer Ingelheim International GmbH

Inventors Schaenzle, Gerhard; Doods, Henri; Paleari, Fabio; Dreyer, Alexander; Mueller, Stephan Georg; Stenkamp, Dirk; Lustenberger, Philipp; Arndt, Kirsten; Rudolf, Klaus; Santagostino, Marco

Agent Davies Collison Cave

Pub. Number AU-A-2006226544

PCT Pub. Number WO2006/100026

Priority PCT/ EP2005/003094 23.03.05 EP

Filing date 21 March 2006

Wipo publication date 28 September 2006

International Classifications

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

A61P 25/06 (2006.01) Drugs for disorders of the nervous system

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

1 November 2007 PCT application entered the National Phase

  PCT publication WO2006/100026 Priority application(s): WO2006/100026

20 October 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006226554-3, 4-substituted pyrrolidine derivatives for the treatment of hypertension

2006226543-Use of an influenza virus an oil-in-water emulsion adjuvant to induce CD4 T-cell and/or improved B-memory cell response